Approaches to gene therapy for human immunodeficiency virus infection

Human Gene Therapy

Volumn 12, Issue 9, 2001, Pages 1013-1019

  Buchschacher, Jr ^a   Wong Staal, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY RNA; GAG PROTEIN; REV PROTEIN; RIBOZYME; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOTHERAPY; EPIDEMIC; GENE THERAPY; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0034924965     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750214249     Document Type: Review

References (63)

1. Lentiviral vector - The promise of gene therapy within reach?
2. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cellsin vitro and in a SCID-hu mouse modelin vivo
3. Dendritic cells and the control of immunity
4. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model
5. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes
6. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit HIV replication
7. Molecular targets of gene transfer therapy for HIV infection
8. Development of lentiviral vectors for gene therapy for human diseases
9. Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus
10. Inhibition of HIV-1 replication and reactivation from latency by tat trans-dominant negative mutant in the cysteine-rich region
11. Human gene therapy and genetically modified stem cells for the treatment of AIDS
12. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
13. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system
14. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
15. Stem cell directed gene therapy
16. RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells
17. Intracellular immunization: Trans-Dominant mutants of HIV gene products as tools for the study and interruption of viral replication
18. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5
19. HIV-protease inhibitors
20. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity
21. Sequence specific cleavage of the HIV-1 co-receptor CCR5 gene by a hammerhead ribozyme and a DNA-enzyme: Inhibition of the co-receptor function by DNA-enzyme
22. A hammerhead ribozyme targeted to the human chemokine receptor CCR5
23. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro
24. Critical factors influencing stable transduction of human CD34+ cells with HIV-1-derived lentiviral vectors
25. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest
26. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: Breadth and specificity of the response and relation to in vivo and in vitro viral quasi-species in a person with prolonged infection and low viral load
27. Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells
28. Dendritic cells: Unique leukocyte populations which control the primary immune response
29. Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor
30. Gene therapy for HIV infection
31. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children
32. Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies
33. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression
34. Multimeric ribozymes against CCR5 mRNA: A novel strategy to inhibit HIV replication
35. Ribozymes in gene therapy of HIV-1
36. Functional dissection of the HIV-1 Rev trans-activator -Derivation of a trans-dominant repressor of Rev function
37. Ribozyme-mediated inhibition of HIV-1 suggests nucleolar trafficking of HIV-1 RNA
38. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
39. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active retroviral therapy
40. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
41. In vivo gene delivery and stable transduction on nondividing cells by a lentiviral vector
42. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme
43. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
44. Combined strategies for gene therapy of AIDS
45. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression
46. A transdominant tat mutant that inhibits Tat-induced gene expression from the human immunodeficiency virus long terminal repeat
47. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals
48. Ribozymes as potential anti-HIV therapeutic agents
49. Protective immunity against HIV infection: Has nature done the experiment for us?
50. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults
51. New anti-HIV drugs and treatment strategies buoy AIDS researcher
52. Hematopoietic stem cell-based gene therapy for AIDS: Efficient transduction and expression of RevM10 in myeloid cellsin vivo and in vitro
53. Over expression of TAR sequences renders cells resistant to human immunodeficiency virus replication
54. Ribozymes: The characteristics and properties of catalytic RNAs
55. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus
56. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells
57. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells
58. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients
59. Testing the promise of gene therapy
60. A controlled, phase I clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
61. Intracellular immunization of human T-cells with a hairpin ribozyme against human immunodeficiency virus type 1
62. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1
63. Progress towards gene therapy for HIV infection